IGF1 and breast cancer: We aim to address the following questions: (1) Whether β-catenin is direct target of miR-152 in breast cancer; (2) whether miR-152 overexpression inhibits cell proliferation by inhibiting both β-catenin and PKM2 expression; (3) what is role of miR-152 in breast cancer resistance to paclitaxel treatment; (4) whether miR-152 is involved in IGF-1-induced β-catenin and PKM2 expression.